Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | TK2 | O00142 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | TYMP | P19971 | 1/20 | 0.31 |
| ▸ | TYMS | P04818 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13032480 | 1.00 | DRD2 (0.33) | DRD2DRD3RNASE1CA4CA12 | |
| SCHEMBL13032488 | 0.93 | TK2 (0.33) | RNASE1TK2TYMPTYMS | |
| SCHEMBL13610657 | 0.93 | TK2 (0.33) | RNASE1TK2TYMPTYMS | |
| SCHEMBL12259021 | 0.91 | DRD2 (0.33) | DRD2DRD3CA4CA12OPRM1 | |
| SCHEMBL12259025 | 0.83 | TYMS (0.32) | TK2TYMPTYMS | |
| SCHEMBL13610655 | 0.83 | CA4 (0.30) | DRD2DRD3CA4CA12OPRM1 | |
| SCHEMBL12259020 | 0.83 | CA4 (0.30) | DRD2DRD3CA4CA12OPRM1 | |
| SCHEMBL13032473 | 0.79 | EPHA2 (0.40) | — | |
| SCHEMBL13610652 | 0.79 | EPHA2 (0.40) | — | |
| SCHEMBL13610651 | 0.76 | POLA1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404862-B2 | Ligand-conjugated monomers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20090286973-A1 | LIGAND-CONJUGATED MONOMERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-7582744-B2 | containing 2'-O-methyl modified nucleoside; oligonucleotide having a nucleotide sequence consisting of from 12 to 23 nucleotides in length sufficiently complementary to a microRNA target sequence of about 12 to 23 nucleotides, conjugate with a cholesterol or steroid; for inhibiting gene expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20070105803-A1 | Methods and compositions for treating neurological disease | MASSACHUSETTS, UNIVERSITY OF | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105803-A1 | Methods and compositions for treating neurological disease | SMN1; SMN2, CLN6, INA | DRD2 4661/4885DRD3 4639/4885RNASE1 85/4885 |
| US-20090286973-A1 | LIGAND-CONJUGATED MONOMERS | TNFSF11, BCDIN3D, CD40LG | DRD2 3809/4885DRD3 4069/4885RNASE1 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.